US FDA approves Ionis' drug for rare genetic disorder
21/08/2025 16:47
Aug 21 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' IONS.O drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder. (Reporting by Bageshri Banerjee and Sneha S K in Bengaluru; Editing by Tasim Zahid) ((bageshri.banerjee@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors